Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 8/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313386 | 0.87 | IMPDH2 (0.35) | IMPDH2GSK3BMEN1KMT2AGAA | |
| SCHEMBL13753911 | 0.86 | AAK1 (0.33) | IMPDH2AAK1IMPDH1ELANE | |
| SCHEMBL6279232 | 0.86 | GAA (0.34) | IMPDH2GSK3BMEN1KMT2AGAA | |
| SCHEMBL1614459 | 0.84 | DYRK1A (0.38) | IMPDH2AAK1MEN1KMT2AGAA | |
| SCHEMBL13746216 | 0.81 | PTGDR2 (0.32) | IMPDH2GSK3BPTGDR2IMPDH1 | |
| SCHEMBL22591311 | 0.80 | GSK3B (0.33) | IMPDH2GSK3BMEN1KMT2AGAA | |
| SCHEMBL4246037 | 0.73 | ENPP3 (0.34) | PTGDR2ELANE | |
| SCHEMBL13745538 | 0.71 | BRD4 (0.40) | GSK3BMEN1KMT2A | |
| SCHEMBL8320919 | 0.70 | PTGDR2 (0.34) | PTGDR2 | |
| SCHEMBL22591370 | 0.66 | IMPDH2 (0.33) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | IMPDH2 4189/4885AAK1 170/4885GSK3B 201/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | IMPDH2 4142/4885AAK1 182/4885GSK3B 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.